Domainex and Auspherix have expanded their collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics. The program has been extended through to 2017. Since initiating the project in 2014, the companies report progress has been made towards the invention of new compounds with activity against both gram-positive and gram-negative bacteria. The collaboration extension aims both to refine the current chemical series towards selection of novel pre-clinical candida...